Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics

Acta Tropica

Volumn 86, Issue 2-3, 2003, Pages 141-159

  Dayan, A D ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Albendazole; Mebendazole; Pharmacokinetics; Praziquantel; Risk assessment; Toxicity

Indexed keywords

ALBENDAZOLE; MEBENDAZOLE; PRAZIQUANTEL;

DRUG DEVELOPMENT;

ANEMIA; ANTIMICROBIAL ACTIVITY; CARCINOGENICITY; CESTODE; CLONORCHIS; CONFERENCE PAPER; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG SAFETY; FETUS DISEASE; GASTROINTESTINAL HEMORRHAGE; GENITAL SYSTEM; GENOTOXICITY; HEPATOMEGALY; HUMAN; HYPERCHOLESTEROLEMIA; HYPOPLASIA; LEUKOPENIA; MUTAGENICITY; NONHUMAN; OPISTHORCHIS; PARASITOSIS; PREGNANCY; SCHISTOSOMA; TERATOGENICITY; TESTIS DISEASE; TOXICITY TESTING; TREATMENT CONTRAINDICATION; VOMITING; WEIGHT GAIN;

ANIMALIA;

EID: 0038740727     PISSN: 0001706X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0001-706X(03)00031-7     Document Type: Conference Paper

References (62)

1. Aardema M.J., Albertini S., Arni P., Henderson L.M., Kirsch-Volders M., Mackay J.M., Sarrif A.M., Stringer D.A., Taalman R. Aneuploidy: a Report of an ECETOC Task Force. Mutat. Res. 410:1998;3-79.
2. ABPI, 1999a. Compendium of Data Sheets, Eskazole tablets. Datapharm Publications, London, p. 1595.
3. ABPI, 1999b. Compendium of Data Sheets, Vermox tablets. Datapharm Publications, London, p. 671.
4. Amri H.S., Fargetton X., Delatour P., Batt A-M.N. Sulphoxidation of Albendazole by FAD-containing and cytochrome P450-dependent mono-oxygenases from pig liver microsomes. Xenobiotica. 17:1987;1159-1168.
5. Amri H.S., Mothe O., Totis M., Masson C., Batt A-M., Delatour P., Siest G. Albendazole sulfonation by rat liver P-450c. J. Pharmacol. Exp. Ther. 246:1988;758-764.
6. Andrews P., Thomas H., Pohlke R., Seubert J. Praziquantel. Med. Res. Rev. 3:1983;147-200.
7. Bekhti A., Pirotte J. Cimetidine increases serum mebendazole concentrations. Implications for treatment of hepatic hydatid cysts. Br. J. Clin. Pharmacol. 24:1987;390-392.
8. Bittencourt P.R.M., Garcia C.M., Martins R. Phenytoin and carbamezepine decrease oral bioavailability of praziquantel. Neurology. 42:1982;493-499.
9. Braithwaite P.A., Roberts M.S., Allan R.J., Watson T.R. Clinical pharmacokinetics of high dose Mebendazole in patients treated for cystic hydatid disease. Eur. J. Clin. Pharmacol. 22:1982;161-169.
10. Bühring K.U., Diekmann H.W., Müller H., Garbe A., Nowak H. Metabolism of praziquantel in man. Eur. J. Drug Metab. Pharmacokinet. 3:1978;179-190.
11. Capece B.P.S., Castells G., Perez F., Arbois M., Cristòfol C. Pharmacokinetic behaviour of Albendazole sulfoxide enantiomers in male and female sheep. Vet. Res. Commun. 24:2000;339-348.
12. Committee on Mutagenicity, 1996. Aneuploidy in Sections 2.17 and Section 2.18 in Annual Report, UK Department of Health, HMSO, London.
13. Davies D.M., Ferner R.E., de Glanville H. Davies's Textbook of Adverse Drug Reactions. fifth ed:1998;1-971 Chapman and Hall, London.
14. 3H)-mebendazole in man. Br. J. Clin. Pharmacol. 19:1985;79-86.
15. Delatour P., Benoit E., Besse S., Boukraa A. Comparative enantioselectivity in the sulphoxidation of albendazole in man, dogs and rats. Xenobiotica. 21:1991;217-221.
16. Delatour P., Garnier P.F., Benoit E., Longin C. A correlation of the toxicity of Albendazole and oxfendazole with their free metabolites and bound residues. J. Vet. Pharmacol. Ther. 7:1984;139-145.
17. Delatour P., Garnier F., Benoit E., Caude I. Chiral behaviour of the metabolite Albendazole sulphoxide in sheep, goats and cattle. Res. Vet. Sci. 50:1991;134-138.
18. Dollery C.T. Albendazole. second ed Therapeutic Drugs. 1:1999;A51-A53 Churchill Livingstone, Edinburgh.
19. Dollery C.T. Mebendazole. second ed Therapeutic Drugs. 2:1999;M12-M15 Churchill Livingstone, Edinburgh.
20. Dollery C.T. Praziquantel. second ed Therapeutic Drugs. 2:1999;P184-P188 Churchill Livingstone, Edinburgh.
21. Dukes M.N.G., Aronson J.K. Meyler's Side Effects of Drugs. 14th:2000;1-1876 Elsevier, Amsterdam.
22. Edwards G., Breckenridge A.M. Clinical pharmacokinetics of anthelminthic drugs. Clin. Pharmacokinet. 15:1988;67-93.
23. EMEA-European Medicines Evaluation Agency, 1996. Praziquantel Summary Report by CVMP. EMEA/MRL/141/96 September 1996. EMEA, London.
24. EMEA-European Medicines Evaluation Agency, 1997. Albendazole Summary Report by CVMP. EMEA/MRL/247/97-Final. EMEA, London.
25. EMEA-European Medicines Evaluation Agency, 1999. Mebendazole Summary Report by CVMP. EMEA/MRL/625/99-Final. July 1999. EMEA, London.
26. EMEA-European Medicines Evaluation Agency, 2001. Mebendazole Summary Report 2 by CVMP. EMEA/MRL/781/01-Final. March 2001. EMEA, London.
27. Fargetton X., Galtier P., Delatour P. Sulfoxidation of Albendazole by a cytochrome P-450 independent monooxygenase from rat liver microsomes. Vet. Res. Commun. 10:1986;314-324.
28. Frohberg H. Propriedades farmocinéticas, farmacologicas y toxicológicas. Salud Publica Mex. 24:1982;605-623.
29. Frohberg H. Results of toxicological studies on praziquantel. Arzneim-Forsch/Drug Res. 34:1984;1137-1144.
30. Frohberg H. The toxicological profile of praziquantel in comparison to other anthelminthics drugs. Acta Leidensia. 57:1989;201-215.
31. Frohberg H., Schulze-Schencking M. Toxicological profile of praziquantel, a new drug against cestode and schistosome infections, as compared to some other schistosomicides. Arzneim-Forsch/Drug Res. 31:1981;555-565.
32. Gotschall D.W., Theorides V.J., Wang R. The metabolism of benzimidazole anthelminthics. Parasitol. Today. 6:1990;115-124.
33. Gray, J., 1999. Mebendazole: commentary on the mutagenic potential. Report from Covance Laboratories, Harrogate, UK, to the Janssen Research Foundation; 7th March, 1999, pp. 1-31.
34. Gyurik R.J., Chow A.W., Zaber B., Brunner E.L., Miller J.A., Villani A.J., Petka L.A., Parish R.C. Metabolism of albendazole in cattle, sheep, rats and mice. Drug Met. Disposit. 9:1981;503-508.
35. Homeida M., Leahy W., Copeland S., Ali M.M.M., Haron D.W.G. Pharmacokinetic interaction between praziquantel and Albendazole in Sudanese men. Ann. Trop. Med. Parasitol. 88:1994;551-559.
36. JECFA, 1989a. Albendazole: in Evaluation of Certain Veterinary Drug Residues in Food. In: Thirty-fourth Report of the Joint WHO/FAO Expert Committee on Food Additives, WHO, Geneva, pp. 14-19.
37. JECFA, 1989b. Albendazole. In: JECFA Food Additives Series 25. Prepared by the Thirty-fourth Meeting of the Joint WHO/FAO Expert Committee on Food Additives, WHO, Geneva, pp. 3-29.
38. Justel A., Alvarez M.L., Alonso J.L., del Estal J.L., Villaverde C., Barrio J.P., Prieto J.G. Influence of ethanol on gastric absorption and metabolism of albendazole and Mebendazole. Drug Alcohol Depend. 36:1994;49-55.
39. Kramers P.G.N., Gentile J.M., Gryseels B.J.A.M., Jordan P., Katz N., Mott K.E., Mulvihill J.J., Seed J.L., Frohberg H. Review of the genotoxicity and carcinogenicity of antischistosomal drugs: Is there a case for a study of mutation epidemiology? Mutat. Res. 257:1991;49-89.
40. Mandour M.l.M., el Turbai H., Homeida M.M., el Sadig T., Ali H.M., Bennett J.L., Leahey W.J., Hassan D.W. Pharmacokinetics of praziquantel in healthy volunteers and patients with schistosomiasis. Trans. R. Soc. Trop. Med. Hyg. 84:1990;389-393.
41. Martindale's Extra Pharmacopoeia, 1993a. In: Reynolds, J.R. (Ed.), Albendazole, 30th Edition. Pharmaceutical Press, London, p. 43.
42. Martindale's Extra Pharmacopoeia, 1993b. In: Reynolds, J.R. (Ed.), Mebendazole, 30th Edition. Pharmaceutical Press, London, p. 46-47.
43. Martindale's Extra Pharmacopoeia, 1993c. In: Reynolds, J.R. (Ed.), Praziquantel, 30th Edition. Pharmaceutical Press, London, p. 52-53.
44. Marques P.d M.C., Takayanagui M., Bonato P.S., Santos S.R.C.J., Lanchote V.L. Enantioselective kinetic disposition of albendazole sulfoxide in patients with neurocysticercosis. Chirality. 11:1999;218-223.
45. Masimirembwa C.M., Hasler J.A. Characterization of praziquantel metabolism by rat liver microsomes using cytochrome P450 inhibitors. Biochem. Pharmacol. 48:1994;1779-1783.
46. Masimirembwa C.M., Naik Y.S., Hasler J.A. The effect of chloroquine on the pharmacokinetics of praziquantel in rats and humans. Biopharm. Drug Dispos. 15:1994;33-43.
47. Moroni P., Burunfosse T., Longin Sauvignon C., Delatour P., Benoit E. Chiral sulfoxidation of Albendazole by the flavin-adenine dinucleotide-containing and cytochrome P450-dependent monooxygenases from rat liver microsomes. Drug Metab. Dispos. 23:1995;160-165.
48. NOAH, 2001. Compendium of Data Sheets for Veterinary Products 2001-2002. NOAH, Middlesex.
49. Okelo G.B.A., Hagos B., Ng'ang'a J.N., Ogeto J.O. Pharmacokinetics of albendazole in children with hydatid disease. E. Afr. Med. J. 70:1993;643-645.
50. PDR, 2001a. Albenza™, 55th ed. Medical Economics, NJ, pp. 3058-3059.
51. PDR, 2001b. Vermox®, 55th Edition. Medical Economics, NJ, p. 1839.
52. PDR, 2001c. Biltricide®, 55th Edition. Medical Economics, NJ, pp. 346-347.
53. Penicaut B., Maugein P., Maisonneuve H., Rossignol J.F. Pharmacokinetics and urinary metabolism of albendazole in man. Bull. Soc. Pathol. Exot. Filiales. 75:1983;698-708.
54. Pütter J., Held F. Quantitative studies on the occurrence of praziquantel in milk and plasma of lactating women. Eur. J. Drug. Metabol. Pharmacokinet. 4:1978;193-198.
55. Rawden H.C., Kokwaro G.O., Ward S.A., Edwards G. Relative contribution of cytochromes P450 and flavin-containing monooxygenases to the metabolism of Albendazole by human liver microsomes. Br. J. Clin. Pharmacol. 49:2000;313-322.
56. Sanchez S., Alvarez L., Sallovitz J., Lanusse C. Enhanced plasma and target tissue availabilities of albendazole and albendazole sulphoxide in fasted calves: evaluation of different fasting intervals. J. Vet. Pharmacol. Ther. 23:2000;193-201.
57. Sanchez S., Sallovitz J., Savio E., McKellar Q., Lanusse C. Comparative availability of two oral dosage forms of albendazole in the dog. Vet. J. 160:2000;153-156.
58. Souhaili-El Amri H., Fargetton X., Benoit E., Totis M., Batt A. Inducing effect of albendazole on rat liver drug-metabolizing enzymes and metabolite pharmacokinetics. Toxicol. Appl. Pharmacol. 92:1988;141-149.
59. Souhaili-El Amri H., Mothe O., Totis M., Masson C., Batt A., Delatour P., Siest G. Albendazole sulfonation by rat liver cytochrome P-450c. J Pharmacol. Exp. Ther. 246:1988;758-764.
60. Thamavit W., Moore M.A., Ruchiraway S., Ito N. Repeated exposure to Opisthorchis viverrini and treatment with the antihelminthic praziquantel lacks carcinogenic potential. Carcinogenesis. 13:1992;309-311.
61. Witassek F., Burkhardt B., Eckhardt J., Bircher J. Chemotherapy of alveolar echinococcosis; comparison of plasma Mebendazole concentrations in animals and man. Eur. J. Clin. Pharmacol. 20:1981;427-433.
62. Zeugin T., Zysset T., Cotting J. Therapeutic monitoring of albendazole: a high-performance liquid chromatography method for determination of its active metabolite albendazole sulfoxide. Ther. Drug Monit. 12:1990;187-190.